Article
Epiregulin and EGFR interactions are involved in pain processing.
The Journal of clinical investigation - 1 Sept 2017
Martin Loren J, Smith Shad B, Khoutorsky Arkady, Magnussen Claire A, Samoshkin Alexander, Sorge Robert E, Cho Chulmin, Yosefpour Noosha, Sivaselvachandran Sivaani, Tohyama Sarasa, Cole Tiffany, Khuong Thang M, Mir Ellen, Gibson Dustin G, Wieskopf Jeffrey S, Sotocinal Susana G, Austin Jean Sebastien, Meloto Carolina B, Gitt Joseph H, Gkogkas Christos, Sonenberg Nahum, Greenspan Joel D, Fillingim Roger B, Ohrbach Richard, Slade Gary D, Knott Charles, Dubner Ronald, Nackley Andrea G, Ribeiro-da-Silva Alfredo, Neely G Gregory, Maixner William, Zaykin Dmitri V, Mogil Jeffrey S, Diatchenko Luda
Abstract excerpt
The EGFR belongs to the well-studied ErbB family of receptor tyrosine kinases. EGFR is activated by numerous endogenous ligands that promote cellular growth, proliferation, and tissue regeneration. In the present study, we have demonstrated a role for EGFR and its natural ligand, epiregulin (EREG), in pain processing. We show that inhibition of EGFR with clinically available compounds strongly reduced nocifensive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
